Novo Nordisk stops Ozempic trial early after signs of early success
CNBC's Angelica Peebles reports on news from Novo Nordisk.
Novo Nordisk Halts Ozempic Study
Novo Nordisk is halting a study which looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. Ed Ludlow reports.
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
Novo Nordisk data knocks $5bn from the value of three leading dialysis companies
Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, No...
Novo Nordisk to stop Ozempic trial to treat renal impairment early
Denmark-based drugmaker Novo Nordisk said on Tuesday it will stop a trial studying Ozempic, its popular diabetes and weight-loss drug, to treat renal impairment in diabetes patients, as its indepen...
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $92.06, denoting a -0.07% change from the preceding trading day.
How Ozempic Accidentally Made Novo Nordisk A $400B Company
Pharmaceutical giant, Novo Nordisk, is now Europe's most valuable company, worth more than its home country, Denmark's total economy. That wasn't always the case, and only recently, through its pop...
Better Growth Stock: Novo Nordisk vs. Pfizer
Pfizer has been actively acquiring companies as it looks to bolster its future growth prospects. Novo Nordisk's top weight-loss drug has more than quadrupled sales and there's more growth ahead.
Both Wall Street and food companies are overreacting to weight-loss drugs, say Herb Greenberg
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy.
Wegovy class has higher GI side effect risk than older weight loss drug in study
Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity...
Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
The study comes as Novo Nordisk's Wegovy, Ozempic and similar treatments skyrocket in popularity in the U.S. for causing dramatic weight loss over time.
Novo Nordisk's Wegovy and Ozempic US patents to be examined by appeal board
One of Novo Nordisk's (NYSE:NVO) US patents for its blockbuster weight-loss drugs Ozempic and Wegovy will be reviewed by the US Patent Office after it was questioned by generic drugmaker Mylan Phar...
Focus: Novo Nordisk's Wegovy bonanza looms large in Denmark
The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk , but also for its home country of Denmark.
Novo Nordisk receives US regulatory go ahead for kidney treatment
Europe's largest drugs company, Novo Nordisk (NYSE:NVO), told investors its once-monthly injection, Rivfloza, has received approval from the US Food and Drug Administration (FDA) for treating a rar...
Related Companies